Treatment of chronic lymphocytic leukaemia with obinutuzumab as a single agent.
Phase of Trial: Phase IV
Latest Information Update: 16 Jul 2015
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.